In the present study, we proposed the combination of a BsAb able to retarget T cells to kill TRAIL-R2-positive cancer cells [6] with selinexor, an inhibitor of XPO1/CRM1 recently approved for the treatment of relapsed/refractory multiple myeloma and currently under clinical development in a variety of hematological and solid tumors [22]. Here, XPO1 is linked to AL amyloidosis.